Pacific Biosciences of California, Inc.
A biotech company that builds machines for reading the long stretches of DNA that make up genes, known as PacBio. Its sequencers use a technology that "eavesdrops" on a single enzyme as it copies DNA, watching each letter being added in real time — used in medical research, agriculture, and microbiology. It was founded in 2004 as Nanofluidics, Inc., renamed Pacific Biosciences of California in 2005 after its home on the Pacific Coast, and launched its first commercial sequencer, the PacBio RS, in 2010.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| ARK Investment Management LLC | 13G/APassive | 9.59% | 29.78M | Aug 14, 2026 |
| Catherine D. Wood | 13G/APassive | 9.59% | 29.78M | Aug 14, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 27, 2026 |
| Gregory Boyd Penner | 13G/APassive | 2.8% | 8.48M | Nov 14, 2025 |
| Madrone Capital Partners, LLC | 13G/APassive | 1.7% | 4.98M | Nov 14, 2025 |
| Madrone Opportunity Fund, L.P. | 13G/APassive | 1.7% | 4.98M | Nov 14, 2025 |
| Jameson J. McJunkin | 13G/APassive | 1.7% | 4.98M | Nov 14, 2025 |
| Thomas Patterson | 13G/APassive | 1.7% | 4.98M | Nov 14, 2025 |
| Shimoda Holdings, LLC | 13G/APassive | 1.2% | 3.50M | Nov 14, 2025 |
| EDMOND DE ROTHSCHILD ASSET MANAGEMENT (FRANCE) | 13G/APassive | 4.5% | 13.37M | Jul 24, 2025 |